公开(公告)号：US20240361688A1

公开(公告)日：2024-10-31

申请号：US18626972

申请日：2024-04-04

申请人： Shin-Etsu Chemical Co., Ltd.

发明人： Masahiro Fukushima

IPC分类号： G03F7/004 ,  C07C25/18 ,  C07C211/63 ,  C07C381/12 ,  C07D207/16 ,  C07D211/46 ,  C07D211/54 ,  C07D211/62 ,  C07D221/14 ,  C07D327/08 ,  C07D333/76 ,  C07D405/12

CPC分类号： G03F7/0045 ,  C07C25/18 ,  C07C211/63 ,  C07C381/12 ,  C07D207/16 ,  C07D211/46 ,  C07D211/54 ,  C07D211/62 ,  C07D221/14 ,  C07D327/08 ,  C07D333/76 ,  C07D405/12

摘要： A chemically amplified resist composition is provided which is excellent in LWR and resolution and can prevent a resist pattern from collapsing in far ultraviolet lithography and EUV lithography, an onium salt for use therein, and a pattern forming process using the resist composition. The chemically amplified resist composition includes an onium salt having the following formula (1).

公开(公告)号：US20240360129A1

公开(公告)日：2024-10-31

申请号：US18763258

申请日：2024-07-03

申请人： Ventus Therapeutics U.S., Inc.

发明人： Stéphane DORICH ,  Jason BURCH ,  Miguel ST-ONGE ,  Amandine CHEFSON ,  Alexandre CÔTÉ ,  Ramsay BEVERIDGE ,  Stéphane CIBLAT

IPC分类号： C07D471/04 ,  A61K31/501 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/5377 ,  C07D405/12 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00

CPC分类号： C07D471/04 ,  A61K31/501 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/5377 ,  C07D405/12 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00

摘要： The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):

公开(公告)号：US20240360128A1

公开(公告)日：2024-10-31

申请号：US18763243

申请日：2024-07-03

申请人： Ventus Therapeutics U.S., Inc.

发明人： Stéphane DORICH ,  Jason BURCH ,  Miguel ST-ONGE ,  Amandine CHEFSON ,  Alexandre CÔTÉ

IPC分类号： C07D471/04 ,  A61K31/501 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/5377 ,  C07D405/12 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00

CPC分类号： C07D471/04 ,  A61K31/501 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/5377 ,  C07D405/12 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00

摘要： The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):

公开(公告)号：US12128028B2

公开(公告)日：2024-10-29

申请号：US17258273

申请日：2019-07-05

申请人： METRION BIOSCIENCES LIMITED

发明人： Marc Rogers ,  Robert Kirby ,  Gakujun Shomi ,  Takuya Matsuo ,  Satoru Kobayashi ,  Junichiro Kanazawa ,  Nobutaka Yamaoka ,  Makoto Torizuka ,  Koichi Suzawa

IPC分类号： A61K31/4164 ,  A61K31/4178 ,  A61K31/439 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/46 ,  A61K31/5377 ,  A61K31/55 ,  C07D233/28 ,  C07D235/02 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D471/08 ,  C07D491/107

CPC分类号： A61K31/4164 ,  A61K31/4178 ,  A61K31/439 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/46 ,  A61K31/5377 ,  A61K31/55 ,  C07D233/28 ,  C07D235/02 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D471/08 ,  C07D491/107

摘要： The invention relates to heterocyclic sulfonamide derivatives and their use in the treatment and prophylaxis of autoimmune, inflammatory, cardiovascular, neuronal, auditory, renal and metabolic mediated diseases, and to compositions containing said derivatives and processes for their preparation.

公开(公告)号：US20240343707A1

公开(公告)日：2024-10-17

申请号：US18631992

申请日：2024-04-10

申请人： Southern Research Institute ,  Oregon Health & Science University

发明人： Syed Kaleem Ahmed ,  Shilpa Dutta ,  Daniel N. Streblow ,  Corinne E. Augelli-Szafran ,  Omar Moukha-Chafiq ,  Ali Nakhi ,  Ashish Kumar Pathak

IPC分类号： C07D401/12 ,  A61K31/505 ,  A61K31/506 ,  A61K31/55 ,  A61K31/675 ,  A61P31/14 ,  C07D239/26 ,  C07D403/12 ,  C07D405/12 ,  C07D513/12 ,  C07F9/6512

CPC分类号： C07D401/12 ,  A61K31/505 ,  A61K31/506 ,  A61K31/55 ,  A61K31/675 ,  A61P31/14 ,  C07D239/26 ,  C07D403/12 ,  C07D405/12 ,  C07D513/12 ,  C07F9/6512

摘要： The present disclosure is concerned with substituted phenyl ethynyl pyrimidine compounds that are capable of inhibiting a viral infection and methods of treating alphavirus viral infections such as, for example, chikungunya, Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), and Venezuelan equine encephalitis using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US12116375B2

公开(公告)日：2024-10-15

申请号：US18490700

申请日：2023-10-19

申请人： The Regents of the University of California

发明人： Jonathan Ostrem ,  Ulf Peters ,  Kevan M. Shokat

IPC分类号： C07D409/04 ,  A61K38/17 ,  C07C235/20 ,  C07C317/08 ,  C07D207/14 ,  C07D211/58 ,  C07D211/62 ,  C07D231/40 ,  C07D295/185 ,  C07D295/26 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  C07D495/04 ,  C12N9/14 ,  C12Q1/6886

CPC分类号： C07D495/04 ,  A61K38/1709 ,  C07C235/20 ,  C07C317/08 ,  C07D207/14 ,  C07D211/58 ,  C07D211/62 ,  C07D231/40 ,  C07D295/185 ,  C07D295/26 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12 ,  C07D409/04 ,  C07D413/12 ,  C07D417/12 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  C12N9/14 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Y306/05002 ,  G01N2500/04

摘要： K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.

公开(公告)号：US12116346B2

公开(公告)日：2024-10-15

申请号：US18136025

申请日：2023-04-18

申请人： BioCryst Pharmaceuticals, Inc.

发明人： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Minwan Wu ,  Venkat R. Chintareddy ,  V. Satish Kumar ,  Weihe Zhang

IPC分类号： C07D231/14 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12

CPC分类号： C07D231/14 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12

摘要： Disclosed are compounds of formula I






as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

公开(公告)号：US12115226B2

公开(公告)日：2024-10-15

申请号：US17271882

申请日：2019-08-28

申请人： Academy of Military Medical Sciences

发明人： Xinbo Zhou ,  Yanming Wang ,  Song Li ,  Wu Zhong ,  Shiyong Fan ,  Dian Xiao ,  Junhai Xiao ,  Zhibing Zheng ,  Xingzhou Li ,  Yunde Xie ,  Ruiyuan Cao ,  Xiaokui Wang

IPC分类号： A61K47/68 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/537 ,  A61K31/5517 ,  A61K31/704 ,  A61K38/07 ,  A61K47/54 ,  A61P35/00 ,  C07C237/04 ,  C07D207/452 ,  C07D233/94 ,  C07D307/71 ,  C07D333/44 ,  C07D403/04 ,  C07D405/12 ,  C07D409/12

CPC分类号： A61K47/6811 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/537 ,  A61K31/5517 ,  A61K31/704 ,  A61K38/07 ,  A61K47/545 ,  A61K47/6803 ,  A61K47/6809 ,  A61P35/00 ,  C07C237/04 ,  C07D207/452 ,  C07D233/94 ,  C07D307/71 ,  C07D333/44 ,  C07D403/04 ,  C07D405/12 ,  C07D409/12

摘要： The present application relates to a linker containing arylnitro, an antibody-drug conjugate the linker and use of the linker, as well as a pharmaceutical composition comprising the antibody-drug conjugate and use of the antibody-drug conjugate for treatment and/or prevention of a disease

公开(公告)号：US20240336571A1

公开(公告)日：2024-10-10

申请号：US18749828

申请日：2024-06-21

申请人： ICAGEN, LLC ,  HOFFMANN-LA ROCHE INC.

发明人： Mark CHAPMAN ,  Nicholas Gareth Morse DAVIES ,  Aaron GERLACH ,  Christopher John GRAHAM ,  Sylvain LEBRETON ,  Ronghua LI ,  Nina MA ,  Daniel MADDOX ,  Ingrid MECHIN ,  David MOWREY ,  Karthigeyan NAGARAJAN ,  Anil NAIR ,  Roger David NORCROSS ,  Roger Lluis REDONDO PENA ,  Alena SAFAROVA ,  Martin SMRCINA

IPC分类号： C07D221/00 ,  A61K31/4433 ,  A61K31/4439 ,  C07D239/26 ,  C07D401/04 ,  C07D405/12 ,  C07D413/04 ,  C07D417/04

CPC分类号： C07D221/00 ,  A61K31/4433 ,  A61K31/4439 ,  C07D239/26 ,  C07D401/04 ,  C07D405/12 ,  C07D413/04 ,  C07D417/04

摘要： The invention provides new heterocyclic compounds having the general formula (I′), or a solvate or a pharmaceutically acceptable salt thereof:






wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

公开(公告)号：US20240336570A1

公开(公告)日：2024-10-10

申请号：US18525253

申请日：2023-11-30

申请人： Escient Pharmaceuticals, Inc.

发明人： Marion Lanier ,  Marcus Boehm ,  Liming Huang ,  Esther Martinborough ,  Marcos Sainz ,  Brandon Selfridge ,  Adam Yeager

IPC分类号： C07D215/46 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D417/12 ,  C07D471/04 ,  C07D495/04 ,  C07D513/04

CPC分类号： C07D215/46 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D417/12 ,  C07D471/04 ,  C07D495/04 ,  C07D513/04

摘要： Methods are provided for modulating MRGPR X2 generally, or for treating a MRGPR X2 or a MRGPR X2 ortholog dependent condition, more specifically, by contacting the MRGPR X2 or the MRGPR X2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I):




or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R1, R2, R3, R4, R5, R6 and Rx are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.